{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:58:54Z","timestamp":1769014734152,"version":"3.49.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.amjcard.2006.11.013","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T12:13:56Z","timestamp":1166876036000},"page":"113-132","source":"Crossref","is-referenced-by-count":75,"special_numbering":"S","title":["Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy"],"prefix":"10.1016","volume":"99","author":[{"given":"Frederick A.","family":"Masoudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2006.11.013_bib1","series-title":"Heart and Stroke Statistics\u20142004 Update","year":"2003"},{"key":"10.1016\/j.amjcard.2006.11.013_bib2","series-title":"2004 National Hospital Discharge Survey. Advance Data From Vital and Health Statistics. Report No. 359","author":"DeFrances","year":"2006"},{"key":"10.1016\/j.amjcard.2006.11.013_bib3","first-page":"S107","article-title":"Economic impact of heart failure in the United States: time for a different approach","volume":"13","author":"O\u2019Connell","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.amjcard.2006.11.013_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/A:1013793621248","article-title":"The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research","volume":"7","author":"Masoudi","year":"2002","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2006.11.013_bib5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJM199711063371906","article-title":"Shattuck lecture\u2014cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities","volume":"337","author":"Braunwald","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib6","series-title":"National Hospital Discharge Survey: Annual Summary 1990","author":"Graves","year":"1992"},{"key":"10.1016\/j.amjcard.2006.11.013_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jama.286.10.1195","article-title":"The continuing epidemics of obesity and diabetes in the United States","volume":"286","author":"Mokdad","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib11","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0735-1097(00)00582-9","article-title":"Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study","volume":"35","author":"Gottdiener","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib12","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib13","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jama.292.3.344","article-title":"Trends in heart failure incidence and survival in a community-based population","volume":"292","author":"Roger","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1067\/mhj.2002.120773","article-title":"Spectrum of heart failure in older patients: results from the National Heart Failure project","volume":"143","author":"Havranek","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2006.11.013_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ahj.2004.04.019","article-title":"Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) prevention trial","volume":"148","author":"Das","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2006.11.013_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archinte.159.5.505","article-title":"Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population","volume":"159","author":"Croft","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0735-1097(01)01408-5","article-title":"Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction","volume":"38","author":"Dries","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0735-1097(03)00856-8","article-title":"The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2003.11.024","article-title":"Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure","volume":"43","author":"Gustafsson","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ejheart.2005.10.005","article-title":"Decreased survival in diabetic patients with heart failure due to systolic dysfunction","volume":"8","author":"Kamalesh","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2006.11.013_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictors of mortality and morbidity in patients with chronic heart failure","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2006.11.013_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.amjcard.2004.12.070","article-title":"Prognostic impact of diabetes mellitus in patients with acute decompensated heart failure","volume":"95","author":"Burger","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.amjmed.2006.05.024","article-title":"Diabetes in heart failure: prevalence and impact on outcome in the population","volume":"119","author":"From","year":"2006","journal-title":"Am J Med"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib25","doi-asserted-by":"crossref","first-page":"6A","DOI":"10.1016\/0735-1097(93)90455-A","article-title":"The epidemiology of heart failure: the Framingham study","volume":"22","author":"Ho","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib26","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.CIR.102.9.1014","article-title":"Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry","volume":"102","author":"Malmberg","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib29","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib30","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.jacc.2003.10.074","article-title":"The association of fasting glucose levels with congestive heart failure in diabetic adults \u226565 years: the Cardiovascular Health Study","volume":"43","author":"Barzilay","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2006.11.013_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1006876607566","article-title":"Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by \u03b1-tocopherol?","volume":"188","author":"Rosen","year":"1998","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.amjcard.2006.11.013_bib33","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/01.CIR.0000012467.61045.87","article-title":"Adaptation and maladaptation of the heart in diabetes. Part II. potential mechanisms","volume":"105","author":"Young","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1009616228304","article-title":"Role of reactive oxygen species (ROS) in apoptosis induction","volume":"5","author":"Simon","year":"2000","journal-title":"Apoptosis"},{"key":"10.1016\/j.amjcard.2006.11.013_bib35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/01.CIR.93.10.1905","article-title":"Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats","volume":"93","author":"Norton","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccl.2004.07.002","article-title":"Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations","volume":"22","author":"Giles","year":"2004","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.amjcard.2006.11.013_bib37","first-page":"1257","article-title":"Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion","volume":"151","author":"Bielawska","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib38","doi-asserted-by":"crossref","first-page":"9320","DOI":"10.1073\/pnas.94.17.9320","article-title":"Targeted overexpression of protein kinase C \u03b22 isoform in myocardium causes cardiomyopathy","volume":"94","author":"Wakasaki","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjcard.2006.11.013_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.294.3.334","article-title":"Insulin resistance and risk of congestive heart failure","volume":"294","author":"Ingelsson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0002-9149(01)02342-6","article-title":"Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure","volume":"89","author":"Parsonage","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib41","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI115260","article-title":"Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans","volume":"87","author":"Anderson","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2006.11.013_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM199602083340607","article-title":"Hypertension and associated metabolic abnormalities\u2014the role of insulin resistance and the sympathoadrenal system","volume":"334","author":"Reaven","year":"1996","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib43","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00005344-200000004-00002","article-title":"Insulin resistance in chronic heart failure","volume":"35","author":"Coats","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00019501-199602000-00002","article-title":"The myocardial and vascular pathology of diabetic cardiomyopathy","volume":"7","author":"Hardin","year":"1996","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.amjcard.2006.11.013_bib45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0002-9149(00)01366-7","article-title":"Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus","volume":"87","author":"Zabalgoitia","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib46","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","article-title":"Impact of diabetes on cardiac structure and function: the Strong heart study","volume":"101","author":"Devereux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib47","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(01)01230-X","article-title":"The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study","volume":"37","author":"Liu","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib48","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cardfail.2005.12.001","article-title":"Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline","volume":"12","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2006.11.013_bib50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib51","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)09374-X","article-title":"Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction","volume":"354","author":"Torp-Pedersen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib56","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib57","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib58","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","article-title":"National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction","volume":"110","author":"Masoudi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib60","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib61","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL [Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan] randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib62","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib63","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1525-1497.2004.30016.x","article-title":"Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough","volume":"19","author":"Morimoto","year":"2004","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib65","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib66","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib69","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib70","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib71","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","article-title":"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the US: 1998-2001","volume":"112","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib73","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib74","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1161\/01.CIR.98.21.2282","article-title":"Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991","volume":"98","author":"Senni","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0735-1097(02)02696-7","article-title":"Gender, age, and heart failure with preserved left ventricular systolic function","volume":"41","author":"Masoudi","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1388-9842(03)00052-7","article-title":"Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"5","author":"McMurray","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2006.11.013_bib77","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0735-1097(03)00185-2","article-title":"Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline","volume":"41","author":"Smith","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diaclin.23.2.64","article-title":"Oral agents for type 2 diabetes: an update","volume":"23","author":"Kimmel","year":"2005","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.013_bib79","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib80","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib81","first-page":"S4","article-title":"Standards of medical care in diabetes\u20142006","volume":"29","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2006.11.013_bib83","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1566524053766004","article-title":"Type 2 diabetes, insulin secretion and \u03b2-cell mass","volume":"5","author":"Ahren","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1566524053766022","article-title":"Insulin resistance in type 2 diabetes\u2014role of the adipokines","volume":"5","author":"Arner","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib85","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib86","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1126\/science.1104345","article-title":"Type 2 diabetes\u2014a matter of \u03b2-cell life and death?","volume":"307","author":"Rhodes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2006.11.013_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2005.10.008","article-title":"An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure [clinical investigation]","volume":"151","author":"Eshaghian","year":"2006","journal-title":"Am Heart J"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib88","first-page":"S20","article-title":"The place of sulfonylureas in the therapy for type 2 diabetes mellitus","volume":"55","author":"Del","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.013_bib89","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70257-4","article-title":"Meglitinide analogues: a review of clinical data focused on recent trials","volume":"32","author":"Blickle","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjcard.2006.11.013_bib90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/dia.2006.8.385","article-title":"Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes","volume":"8","author":"Kendall","year":"2006","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.amjcard.2006.11.013_bib91","first-page":"CD003639","article-title":"\u03b1-Glucosidase inhibitors for type 2 diabetes mellitus","volume":"2","author":"Van de Laar","year":"2005","journal-title":"Cochrane Database System Rev"},{"key":"10.1016\/j.amjcard.2006.11.013_bib92","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","article-title":"Metformin: new understandings, new uses","volume":"63","author":"Hundal","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.amjcard.2006.11.013_bib93","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib94","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1089\/dia.2004.6.850","article-title":"Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability","volume":"6","author":"Vasudevan","year":"2004","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.amjcard.2006.11.013_bib95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","article-title":"Nonhypoglycemic effects of thiazolidinediones","volume":"134","author":"Parulkar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib96","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/S0002-9343(00)00339-9","article-title":"Combining insulin and oral agents","volume":"108","author":"Buse","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib97","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","article-title":"Pramlintide in the treatment of type 1 and type 2 diabetes mellitus","volume":"27","author":"Ryan","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2006.11.013_bib98","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/01.CIR.94.9.2297","article-title":"Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration","volume":"94","author":"Engler","year":"1996","journal-title":"Circulation"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib99","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.013_bib100","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/diacare.25.12.2244","article-title":"Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes","volume":"25","author":"Johnson","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib101","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/S0167-0115(99)90008-X","article-title":"Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction","volume":"138","author":"Jollis","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2006.11.013_bib102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heart.90.1.9","article-title":"Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?","volume":"90","author":"Meier","year":"2004","journal-title":"Heart"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib103","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.2337\/diabetes.53.suppl_3.S156","article-title":"The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium","volume":"53","author":"Quast","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.013_bib104","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1046\/j.1460-9592.2003.t01-1-00177.x","article-title":"Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure","volume":"26","author":"Aronson","year":"2003","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/jpet.104.073890","article-title":"Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines","volume":"312","author":"Nikolaidis","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2006.11.013_bib106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10557-005-6892-4","article-title":"Glucagon like peptide-1 is protective against myocardial ischemia\/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model","volume":"19","author":"Bose","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2006.11.013_bib107","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib108","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/01.CIR.0000116762.77804.FC","article-title":"Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction","volume":"109","author":"Chaudhuri","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib109","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/diabetes.55.02.06.db05-1023","article-title":"Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease","volume":"55","author":"Lautamaki","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.013_bib110","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1161\/CIRCULATIONAHA.104.497461","article-title":"Insulin causes [Ca2+]i-dependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium","volume":"111","author":"von Lewinski","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib111","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","article-title":"Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus","volume":"314","author":"Malmberg","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2006.11.013_bib112","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1172\/JCI107996","article-title":"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man","volume":"55","author":"DeFronzo","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2006.11.013_bib113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/dmrr.480","article-title":"The incidence of congestive heart failure associated with antidiabetic therapies","volume":"21","author":"Nichols","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.amjcard.2006.11.013_bib114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ahj.2004.07.005","article-title":"Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure","volume":"149","author":"Smooke","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2006.11.013_bib115","first-page":"398","article-title":"Metformin-associated lactic acidosis: case reports and literature review","volume":"15","author":"Chang","year":"2002","journal-title":"J Nephrol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib116","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diacare.22.6.925","article-title":"Incidence of lactic acidosis in metformin users","volume":"22","author":"Stang","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib117","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"338","author":"Misbin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib118","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1464-5491.2001.00509.x","article-title":"Contraindications to metformin therapy in patients with type 2 diabetes\u2014a population-based study of adherence to prescribing guidelines","volume":"18","author":"Emslie-Smith","year":"2001","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib119","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1464-5491.1999.00115.x","article-title":"Contra-indications to metformin therapy are largely disregarded","volume":"16","author":"Holstein","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib120","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib121","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.290.1.81","article-title":"Metformin and thiazolidinedione use in Medicare patients with heart failure","volume":"290","author":"Masoudi","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.013_bib122","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib123","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2337\/diacare.27.7.1791","article-title":"The phantom of lactic acidosis due to metformin in patients with diabetes","volume":"27","author":"Misbin","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib124","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2337\/diacare.28.10.2585","article-title":"Metformin and heart failure: innocent until proven guilty","volume":"28","author":"Inzucchi","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib125","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.013_bib126","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCULATIONAHA.105.549618","article-title":"Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors","volume":"113","author":"Campia","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib127","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjhyper.2005.12.017","article-title":"Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect","volume":"19","author":"Sarafidis","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjcard.2006.11.013_bib128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.0000025403.20953.23","article-title":"Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus","volume":"106","author":"Haffner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib129","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/01.CIR.101.10.1165","article-title":"Troglitazone improves recovery of left ventricular function after regional ischemia in pigs","volume":"101","author":"Zhu","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib130","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1161\/01.CIR.0000039346.31538.2C","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction","volume":"106","author":"Shiomi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.013_bib131","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3949\/ccjm.73.4.390","article-title":"Do thiazolidinediones cause heart failure?","volume":"73","author":"Tang","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib132","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.bjp.0705898","article-title":"Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure","volume":"142","author":"Thiemermann","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib133","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.013_bib134","unstructured":"GlaxoSmithKline Pharmaceuticals. Avandia\u00ae (rosiglitazone maleate) tablets: prescribing information. Available at: http:\/\/us.gsk.com\/products\/assets\/us_avandia.pdf. Accessed January 2, 2004."},{"key":"10.1016\/j.amjcard.2006.11.013_bib135","unstructured":"Takeda Pharmaceuticals. Actos\u00ae (pioglitazone hydrochloride) tablets. Available at: http:\/\/www.actos.com\/pi.pdf. Accessed January 2, 2004."},{"key":"10.1016\/j.amjcard.2006.11.013_bib136","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat Med"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.013_bib137","doi-asserted-by":"crossref","first-page":"111S","DOI":"10.1016\/j.amjmed.2003.09.018","article-title":"Considerations for management of fluid dynamic issues associated with thiazolidinediones","volume":"115","author":"Hollenberg","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib138","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/diab.46.3.433","article-title":"Cardiac and glycemic benefits of troglitazone treatment in NIDDM","volume":"46","author":"Ghazzi","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.013_bib139","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/A:1020696321609","article-title":"Troglitazone improves cardiac function in patients with congestive heart failure","volume":"16","author":"Ogino","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2006.11.013_bib140","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4065\/78.9.1088","article-title":"Thiazolidinedione-associated congestive heart failure and pulmonary edema","volume":"78","author":"Kermani","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2006.11.013_bib141","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjmed.2004.10.010","article-title":"Pioglitazone-induced heart failure despite normal left ventricular function","volume":"117","author":"Shah","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib142","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib143","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1592\/phco.2005.25.10.1329","article-title":"Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study","volume":"25","author":"Hartung","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjcard.2006.11.013_bib144","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1464-5491.2005.01704.x","article-title":"Pioglitazone initiation and subsequent hospitalization for congestive heart failure","volume":"22","author":"Karter","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjcard.2006.11.013_bib145","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/diacare.28.7.1680","article-title":"Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project","volume":"28","author":"Inzucchi","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.013_bib146","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0735-1097(03)00159-1","article-title":"Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure","volume":"41","author":"Tang","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.013_bib147","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906022314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906022314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T15:53:22Z","timestamp":1547135602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914906022314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0002914906022314"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2006.11.013","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}